Al
Non vérifié

Alzheon, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversSantéScience
10/11/2026
Événements
Expos
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé Publique
Santé
Médecine - Divers
Alzheon Highlights ORION-E4 Phase 3 Trial Launch for Oral Valiltramiprosate/ALZ-801 and Expansion of Its Oral Anti-Amyloid Aggregation Inhibitor Portfolio at CTAD 2026 Conference in Boston, November 16–19
1.00
06/07/2026
Événements
Expos
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Médecine - Divers
Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London
1.00
02/12/2025
Science
Finance
Médecine - Divers
Associations/Professionnels
Biotechnologie
Santé Publique
Industrie pharmaceutique
Santé
Industrie
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0